InMed Pharmaceuticals filed a prospectus supplement on April 3, 2026, to sell common shares worth up to $1,213,648 under its existing At The Market Offering Agreement with H.C. Wainwright & Co.
Key takeaways
The Company may sell common shares with an aggregate sales value of up to $1,213,648.
Sales will be conducted through H.C. Wainwright & Co., LLC acting as sales agent under the ATM Agreement.
The offering utilizes the effective shelf Registration Statement on Form S-3 (File No. 333-294503).
Common shares issued will be validly issued, fully paid, and non-assessable.